RVTY - Revvity Inc
94.00
| Index: | S&P 500 | P/E: | 37.17 | EPS (ttm): | 2.53 | Insider Own: | 0.42% | Shs Outstand: | 119.41M | Perf Week: | -4.57% |
| Market Cap: | 11.08B | Forward P/E: | 17.16 | EPS next Y: | 5.48 | Insider Trans: | -7.65% | Shs Float: | 117.37M | Perf Month: | 2.37% |
| Income(ttm): | 309.55M | PEG: | 4.83 | EPS next Q: | 1.14 | Inst Own: | 98.45% | Short Float: | 4.35% | Perf Quarter: | -15.88% |
| Revenue(ttm): | 2.77B | P/S: | 4.00 | EPS this Y: | 0.44% | Inst Trans: | 2.90% | Short Ratio: | 4.11 | Perf Half Y: | -21.50% |
| Book/sh: | 63.96 | P/B: | 1.47 | EPS next Y: | 11.31% | ROA: | 2.30% | Short Interest: | 5.11M | Perf Year: | -12.40% |
| Cash/sh: | 9.66 | P/C: | 9.73 | EPS next 5Y: | 7.69% | ROE: | 3.82% | 52W Range: | 88.53 - 129.50 | Perf YTD: | -15.78% |
| Dividend Est.: | 0.27 (0.29%) | P/FCF: | 21.24 | EPS past 5Y: | 3.37% | ROI: | 2.82% | 52W High: | -27.41% | Beta: | 0.97 |
| Dividend TTM: | 0.28 (0.30%) | Quick Ratio: | 2.99 | Sales past 5Y: | 0.42% | Gross Margin: | 52.61% | 52W Low: | 6.18% | ATR (14): | 3.85 |
| Dividend Ex-Date: | Jul 18, 2025 | Current Ratio: | 3.58 | EPS Y/Y TTM: | 78.53% | Oper. Margin: | 15.32% | RSI (14): | 48.18 | Volatility: | 4.23% 3.70% |
| Employees: | 11000 | Debt/Eq: | 0.44 | Sales Y/Y TTM: | 1.62% | Profit Margin: | 11.18% | Recom: | 2.05 | Target Price: | 118.00 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.44 | EPS Q/Q: | 53.57% | Payout: | 11.63% | Rel Volume: | 0.47 | Prev Close: | 93.26 |
| Sales Surprise: | 0.61% | EPS Surprise: | 6.46% | Sales Q/Q: | 2.28% | Earnings: | Apr 28 BMO | Avg Volume: | 1.24M | Price: | 94.00 |
| SMA20: | 0.62% | SMA50: | -5.58% | SMA200: | -17.36% | Undervalued: 25.53% | Volume: | 570,128 | Change: | 0.79% | |
Graham Classic formula value: 54.25
(P/E=8 * 1g) Min value: 35.65
(current P/E * 2g) Max value: 119.39
Average value: 69.76
About Revvity Inc
Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.